Patents Assigned to Amgen
  • Antibodies to cyclin E2 protein
    Publication number: 20050282150
    Abstract: Disclosed are nucleic acid molecules encoding novel cyclin E2 polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Application
    Filed: July 28, 2005
    Publication date: December 22, 2005
    Applicant: Amgen Inc.
    Inventors: Steven Coats, Michael Bass, Murray Robinson
  • Substituted piperidines and methods of use
    Patent number: 6977264
    Abstract: Selected substituted piperidine compounds are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: December 20, 2005
    Assignee: Amgen Inc.
    Inventors: Christopher H. Fotsch, Michael Croghan, Elizabeth M. Doherty, Michael G. Kelly, Mark H. Norman, Duncan M. Smith, Nuria Tamayo, Ning Xi, Shimin Xu
  • Aryl sulfonamide compounds and uses related thereto
    Publication number: 20050277649
    Abstract: The present invention provides Aryl Sulfonamide Compounds having the formula: and prodrugs or pharmaceutically acceptable salts or prodrugs thereof. The Aryl Sulfonamide Compounds are useful for treating diabetes, obesity, and other diseases and disorders.
    Type: Application
    Filed: December 20, 2004
    Publication date: December 15, 2005
    Applicants: Amgen SF, LLC, Japan Tobacco, Inc.
    Inventors: Michael DeGraffenreid, Xiao He, Jay Powers, Daqing Sun, Xuelei Yan
  • NTR3, a novel member of the TNF- receptor supergene family
    Publication number: 20050277151
    Abstract: The present invention provides a purified polynucleotide encoding a novel receptor, designated NTR3, which belongs to the TNF receptor gene superfamily; to purified NTR3 polypeptide molecules; to antibodies that bind NTR3; to materials comprising such molecules; and to methods of using such molecules.
    Type: Application
    Filed: June 16, 2005
    Publication date: December 15, 2005
    Applicant: AMGEN INC.
    Inventor: Halling Hsu
  • Gene amplification in cancer
    Patent number: 6974672
    Abstract: There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the CTSZ and CD24 genes, which are amplified colon cancer and/or ovarian cancer and/or breast cancer genes. The CTSZ and CD24 genes, their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or vaccine; they also are used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: December 13, 2005
    Assignee: Amgen Inc.
    Inventors: Scott Powers, Jianxin Yang
  • Pyrazole compounds and uses related thereto
    Publication number: 20050272793
    Abstract: Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome.
    Type: Application
    Filed: March 18, 2005
    Publication date: December 8, 2005
    Applicant: Amgen Inc.
    Inventors: Hiroyuki Goto, Makoto Kakutani, Jun Nishiu, Yasuhiro Ohe, Jay Powers, Shinji Yata
  • G-CSF analog compositions and methods
    Publication number: 20050260154
    Abstract: The present invention relates to granulocyte colony-stimulating factor (“G-CSF”) hybrid molecules which retain the internal core helices of G-CSF. Also provided are pharmaceutical compositions containing hybrid molecules.
    Type: Application
    Filed: April 25, 2005
    Publication date: November 24, 2005
    Applicant: AMGEN INC.
    Inventor: Timothy Osslund
  • Method for increasing hematopoietic progenitor cells by stem cell factor
    Patent number: 6967029
    Abstract: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: November 22, 2005
    Assignee: Amgen Inc.
    Inventors: Krisztina M. Zsebo, Robert A. Bosselman, Sidney V. Suggs, Francis H. Martin
  • Substituted heterocyclic compounds and methods of use
    Patent number: 6967254
    Abstract: The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic ? cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: November 22, 2005
    Assignee: Amgen Inc.
    Inventors: Celia Dominguez, Dawei Zhang, Kelvin K. C. Sham, Guo-Qiang Cao
  • Substituted pyrido[2,3-d]pyrimidines and methods for their use
    Patent number: 6964967
    Abstract: Compounds having the formula: wherein A4 is N and X is —C(O)— or —CH2—, are provided, which are useful as modulators of a chemokine receptor and for treatment of inflammatory and immunoregulatory disorders and diseases. Pharmaceutical compositions and methods of using these compounds for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes, are also provided.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: November 15, 2005
    Assignee: Amgen, Inc.
    Inventors: Alan Xi Huang, Michael G. Johnson, An-Rong Li, Jiwen Liu, Julio C. Medina
  • Inhibitors of apoptosis
    Patent number: 6964765
    Abstract: The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis, for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes. The invention includes methods of using the subject compositions in therapy, in diagnosis and in the biopharmaceutical industry.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: November 15, 2005
    Assignee: Amgen, Inc.
    Inventors: Mike Rothe, David V. Goeddel
  • Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
    Publication number: 20050250854
    Abstract: Combination therapies are provided for the treatment of proliferative disorders which use a pentafluorobenzenesulfonamide of formula I and an antineoplastic agent.
    Type: Application
    Filed: November 23, 2004
    Publication date: November 10, 2005
    Applicants: Amgen Inc., Health Research, Inc.
    Inventors: Fengzhi Li, Xiang Ling, Youcef Rustum, Susan Schwendner, Pieter Timmermans, Jacqueline Walling
  • Therapeutic modulation of PPARgamma activity
    Publication number: 20050250820
    Abstract: Modulators of PPAR? activity are used in methods of treating and/or preventing conditions such as osteoporosis, Alzheimer's disease, psoriasis and acne, and cancer.
    Type: Application
    Filed: March 7, 2005
    Publication date: November 10, 2005
    Applicant: Amgen Inc.
    Inventor: Jin-Long Chen
  • Chandra: a Th1-specific protein
    Patent number: 6956105
    Abstract: The present invention provides nucleic acid and protein sequences for a novel Th-1 cell-specific protein, Chandra. The herein-disclosed sequences can be used for any of a number of purposes, including for the specific detection of Th1 lymphocytes, for the identification of molecules that associate with and/or modulate the activity of Chandra, to diagnose any of a number of conditions associated with Th1 or Th2 cell activity, or to modulate the number and/or activity of Th1 or Th2 lymphocytes in a mammal.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: October 18, 2005
    Assignee: Amgen Inc.
    Inventors: Ulrike Schindler, Chandrasekar Venkataraman
  • N-terminally chemically modified protein compositions and methods
    Patent number: 6956027
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: October 18, 2005
    Assignee: Amgen Inc.
    Inventor: Olaf B. Kinstler
  • Chordin-like molecules and uses thereof
    Publication number: 20050226866
    Abstract: The present invention provides Chordin-Like (CHL) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with CHL polypeptides.
    Type: Application
    Filed: June 3, 2005
    Publication date: October 13, 2005
    Applicant: Amgen Inc.
    Inventors: Naoki Nakayama, Duanzhi Wen, Chun-Ya Han, Ching He, Dongyin Yu
  • Chordin-like molecules and uses thereof
    Publication number: 20050214910
    Abstract: The present invention provides Chordin-Like (CHL) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with CHL polypeptides.
    Type: Application
    Filed: June 3, 2005
    Publication date: September 29, 2005
    Applicant: Amgen Inc.
    Inventors: Naoki Nakayama, Duanzhi Wen, Chun-Ya Han, Ching He, Dongyin Yu
  • Chordin-like molecules and uses thereof
    Publication number: 20050214252
    Abstract: The present invention provides Chordin-Like (CHL) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with CHL polypeptides.
    Type: Application
    Filed: June 3, 2005
    Publication date: September 29, 2005
    Applicant: Amgen Inc.
    Inventors: Naoki Nakayama, Duanzhi Wen, Chun-Ya Han, Ching He, Dongyin Yu
  • Chordin-like molecules and uses thereof
    Publication number: 20050214856
    Abstract: The present invention provides Chordin-Like, (CHL) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with CHL polypeptides.
    Type: Application
    Filed: June 3, 2005
    Publication date: September 29, 2005
    Applicant: Amgen Inc.
    Inventors: Naoki Nakayama, Duanzhi Wen, Chun-Ya Han, Ching He, Dongyin Yu
  • Cytokines that bind the cell surface receptor hek
    Patent number: 6949366
    Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.
    Type: Grant
    Filed: July 12, 2001
    Date of Patent: September 27, 2005
    Assignee: Amgen Inc.
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti